Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension.
about
Evening versus morning dosing regimen drug therapy for hypertensionTiming of Administration: For Commonly-Prescribed Medicines in AustraliaTherapeutic applications of circadian rhythms for the cardiovascular systemMolecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.Time of administration important? Morning versus evening dosing of valsartanCan nocturnal hypertension predict cardiovascular risk?Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease?Benefits of once-daily therapies in the treatment of hypertension.Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysisAntihypertensive therapy: nocturnal dippers and nondippers. Do we treat them differently?Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension.Management of nocturnal hypertension.Nocturnal nondipping and left ventricular hypertrophy in hypertension: an updated review.Nocturnal medications dosing: does it really make a difference in blood pressure control among patients with chronic kidney disease?Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation.Chronotherapy improves blood pressure control and reduces vascular risk in CKD.Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.Treatment of hypertension with chronotherapy: is it time of drug administration?Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.Hyperuricaemia is associated with renal damage independently of hypertension and intrarenal renin-angiotensin system activation, as well as their circadian rhythms.Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension.Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals.Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension.Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction.Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients.Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension.Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications.Chronotherapy with low-dose aspirin for prevention of complications in pregnancy.Sleep-time ambulatory blood pressure as a prognostic marker of vascular and other risks and therapeutic target for prevention by hypertension chronotherapy: Rationale and design of the Hygia Project.Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation.Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk.Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes.Administration-time-dependent effects of hypertension treatment on ambulatory blood pressure in patients with chronic kidney disease.Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.The optimal timing of antihypertensive medication administration for morning hypertension in patients with cerebral infarction.
P2860
Q24236288-79B24E6B-179D-43EF-BB86-3C7E08CDDAB6Q26752357-B888F802-20F9-425A-878D-A1F530579B42Q28080493-B95D7109-72CA-4D87-B475-6F7FB790D79AQ33648966-E390B1B9-5ED9-4D91-AE44-A993B7ED2850Q34823252-3F33071C-2795-489B-B53B-25D304BF49D9Q35210578-5AFE46C8-BE37-4072-8B21-91C0549815A5Q35400901-5FE4C74C-192D-4F46-9221-6872BC48F236Q35660819-3961D045-677B-4C05-9E5A-366B685C7B5CQ36122212-476E94F5-3645-4CAC-BE8A-C9CD84A91054Q36739157-085C1F51-052F-4851-8094-0B0F06EEFCFAQ37201615-44E9F948-D37A-439E-9A94-5D21C7134806Q37510981-3340D7C5-1669-4E9A-A7DA-FBA5E119489EQ37763197-601BBCFB-529A-4536-9700-2FA32CBDAA9EQ38029919-F7D2F41D-17C3-44E8-A71E-2C7F21989989Q38053166-9EDC09F7-42A0-4358-A943-6357FEB02BA0Q38100986-91C8DE38-AA5B-46FC-A8EC-4BE3AF1B77A1Q38130648-F168C6B9-893D-427A-BA13-63CAF115D02BQ38177166-8CACC779-C30B-4AD6-B136-340437643379Q38291112-E78B7CC1-70B2-42E4-A7E7-926002E21360Q39541406-3F1DBAA6-DEB1-4993-B55E-902C4DD4BEE4Q40945376-13A9C347-BA96-40AE-BE76-7F354F734FA6Q42960996-E906A459-B63A-4CD9-A5DA-2517F4BC187BQ43044200-A7920668-D655-4B0F-B13A-D993404D0A25Q44009304-D1F7AC52-AF41-4327-B225-69EB57DC160FQ44360459-ED311660-ADF7-45A7-8A20-42F2F66E744BQ44373377-CDCB453B-FF53-42F0-AD41-F7493B62532DQ45394467-42DA3CDC-1305-4497-AD76-F61F665CA046Q46163937-B427664A-67A6-4B7A-8E3F-1D2B681355FAQ46249688-82425898-0BA5-4689-A9BA-0BFE5CAB24B6Q46880145-FE8ADA39-9E39-4154-90F1-EC0D48E29760Q47831280-3B79CC5D-39F7-440A-B362-57F5C30C502CQ47853674-246E8669-2F56-4974-9F77-B859487299A5Q47876193-C5F4D05B-CE6F-45C3-8429-0B678705273FQ47910182-3A98FB07-61C2-4583-B3FB-D8DF34B5C2C7Q48210056-0FF5484B-CB49-451C-AA58-D68BCF7772B4Q48210138-35464B3B-6BA6-4765-98D2-9A334A556D2FQ48216222-D23D4067-BD05-4DFB-892A-9B3AD52BC299Q48217241-F2309C6F-B264-44C6-8E5C-CE3ECB87D250Q48289407-77B37AD7-580D-4720-96E5-9B1469D448F3Q51356422-85756820-4B7B-406F-B398-F149526E2846
P2860
Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Comparison of the efficacy of ...... tan in essential hypertension.
@ast
Comparison of the efficacy of ...... tan in essential hypertension.
@en
Comparison of the efficacy of ...... tan in essential hypertension.
@nl
type
label
Comparison of the efficacy of ...... tan in essential hypertension.
@ast
Comparison of the efficacy of ...... tan in essential hypertension.
@en
Comparison of the efficacy of ...... tan in essential hypertension.
@nl
prefLabel
Comparison of the efficacy of ...... tan in essential hypertension.
@ast
Comparison of the efficacy of ...... tan in essential hypertension.
@en
Comparison of the efficacy of ...... tan in essential hypertension.
@nl
P2093
P1433
P1476
Comparison of the efficacy of ...... rtan in essential hypertension
@en
P2093
Carlos Calvo
Diana E Ayala
Ramón C Hermida
P304
P356
10.1161/HYPERTENSIONAHA.107.094235
P407
P577
2007-07-16T00:00:00Z